Sandoz Bolsters US Ophthalmic Portfolio With Aflibercept Approval
Launch Date Of Eylea Biosimilar Uncertain As ‘Complicated’ Court Proceedings Continue
• By David Wallace
Sandoz has received FDA approval for its Enzeevu rival to Eylea • Source: Shutterstock 
